Evaxion welcomes Per Norlén as new CEO.
-
COPENHAGEN, Denmark, Oct. 1st, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announces that its new Chief Executive Officer (CEO) Per Norlén has joined the company on October 1st.
Dr. Norlén is a board-certified physician and associate professor with more than 20 years in the biotech sector, of which the last decade has been in executive leadership roles. He brings a wealth of experience from being CEO of listed drug development companies. He has a proven business development track record, including major out-licensing deals with biotech and Pharma.
"Evaxion has emerged from being an under-the-radar start-up to becoming a clinical stage biotech company leading the development of tailored cancer immunotherapies, individually designed for each patient. I am convinced that Evaxion is on to something extremely important that holds the potential to become a game-changer for patients with metastatic cancer. During my previous career, I have always dreamt of making the perfect drug, and I feel enormously privileged to now be part of a team that I believe is doing just that. This is clearly within reach with a newly initiated phase 2b trial in melanoma that will hopefully confirm the very promising phase 1 efficacy signals. I can't wait to get started," says Per Norlén, CEO at Evaxion.
Chairman of the board, Marianne Soegaard, says the new hire signals the next stage for the biotech company:
"With Per at the steering wheel, we expect to bring our promising clinical and preclinical results to the next level. Evaxion is a profoundly innovative and talented company working tirelessly to save patients' lives. Per Norlén is joining the company as an experienced leader bringing the necessary expertise and competences to bring Evaxion from an innovative early stage to the next level. I look forward to having Per on board to help realize the vast potential from our clinical trials, and create personalized therapies for cancer patients and patients suffering from other critical diseases."About Evaxion
Evaxion Biotech A/S is a clinical-stage biotech company developing AI-powered immunotherapies. With our proprietary and scalable AI technology, we decode the human immune system to discover and develop novel immunotherapies for patients suffering from cancer or bacterial and viral infections. Evaxion has a broad pipeline of novel product candidates, including three personalized cancer immunotherapies. We are located in Hørsholm, Denmark, and currently have 70 employees.For more information from Dr. Per Norlén, please contact:
VP, Communications and Public Relations
Katrine Hertz Mortensen
Phone: +45 30 10 02 03
E-mail: [email protected]Evaxion Biotec har en betalt digital IR-aftale med Proinvestor.com
-
Evaxion enrols first patient in phase IIb melanoma study
3 October, 2022
Evaxion Biotech's lead immunotherapy candidate, EVX-01, developed through one of the company's AI platforms, has entered clinical development phase IIb in metastatic melanoma patients. With the announcement of the first patient enrolled in the study, BioStock spoke with Evaxion's CMO Erik Heegaard to learn more about this important milestone.
Read more: https://www.biostock.se/en/2022/10/evaxion-enrols-first-patient-in-phase-iib-melanoma-study/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind